News | May 27, 2026
Jubilant Ingrevia delivers 14-quarter high revenue in Q4 FY26 as margins strengthen across biz
The company highlighted continued demand strength and pricing resilience despite global disruptions
The company highlighted continued demand strength and pricing resilience despite global disruptions
The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank
The company is expected to conduct further studies to confirm the long-term efficacy and safety of Vijoice in both adult and paediatric patients
India already has talent, digital infrastructure, entrepreneurial energy, clinical expertise, and policy momentum. The next phase demands coordinated execution and building institutions that can hold the ecosystem together over time
Fresh data from the State of the World’s Nursing 2025 report shows the global nursing workforce has expanded from 27.9 million in 2018 to 29.8 million in 2023
The decision clears the drug as a monotherapy for adults with unresectable, locally advanced or metastatic non-small cell lung cancer
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
With standout ADC and t-cell engager response data across hard-to-treat cancers
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
